Tag Archives: Bloomberg

China’s FDA to accept foreign trial data for accelerated approvals; sounds great, but future enforcement of IP rights poses threat to US Pharma.

The News: For decades, patients in China have fought to gain access to cutting-edge medicines thanks to bureaucratic delays that have thwarted drug development. Now a sweeping government overhaul of… Read more »

Catabasis soars on fresh Duchenne trial data, proving biotech melt-up still in progress; but for how much longer?

The News: Recuperating from a trial flop involving its lead drug for Duchenne muscular dystrophy, Catabasis Pharmaceuticals Inc. (Cambridge MA) is charging ahead with a late-stage study, hyping new data… Read more »

Humdrum, stodgy Pfizer suddenly turns heads with partial drug-pipeline spinoff; old dog apparently can learn new tricks.

The News: Pfizer Inc. (NYC) on Monday (September 25, 2017) announced that it is spinning off a new company, SpringWorks Therapeutics LLC, to develop several drugs for rare diseases that… Read more »

Alnylam soars on RNAi success as Phase 3 patisiran study hits all goals; market overreacts as pipeline unproven and competition lurks.

The News: Alnylam Pharmaceuticals Inc.’s (Cambridge MA) RNAi-based drug that targets a rare genetic disease cleared a key study, in a breakthrough for the new class of medicines that works… Read more »

Germany’s Merck puts consumer drugs business up for sale; does this signal a last-ditch shot at M&A or just shoring up existing pipeline?

The News: Merck KGaA (Darmstadt DEU) put its consumer-health unit on the block Tuesday (September 5, 2017) in a move that will focus its healthcare activities on the riskier business… Read more »

Obamacare fails to implode as Ohio’s CareSource fills last “bare” US county.

The News: Obamacare plans will be sold in every part of the US next year after an insurer agreed to do business in a small Ohio county, overcoming predictions that… Read more »

Merck’s Frazier leads the way quitting Trump business council after Charlottesville; J&J’s Gorsky’s bail way too late.

The News: One day after J&J chief exec Alex Gorsky pub­licly com­mit­ted to stay­ing on Pres­i­dent Don­ald Trump’s man­u­fac­tur­ing coun­cil, he abruptly re­versed course–just as the sud­den mass departure of ex­ec­u­tives forced… Read more »

Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?

The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »

Americans are sicker, die younger while spending the most on health care; what South Korea can teach us.

The News: Typically, the more a developed country spends on health care, the longer its people live. The US, which spends the most on health care, defies that tendency another… Read more »

UnitedHealthcare 2nd quarter sparkles; but time to figure out how Centene, Molina exploit Medicaid?

The News: UnitedHealth Group Inc.’s (Minnetonka MN) second-quarter earnings jumped 11% to beat analysts’ expectations even though the nation’s largest health insurer took a bigger hit than expected from coverage… Read more »